Related Experiment Videos
Introduction to eicosanoids and the gastroenteric tract
R N DuBois1, C F Eberhart, C S Williams
1Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Gastroenterology Clinics of North America
|June 1, 1996
Summary
Researchers are exploring eicosanoids, crucial for gastrointestinal processes. Understanding cyclooxygenase (COX) enzymes, particularly COX-2, offers potential for new treatments for inflammatory bowel disease (IBD) and NSAID-induced injury.
Area of Science:
- Gastroenterology
- Molecular Biology
- Pharmacology
Background:
- Eicosanoids, derived from arachidonic acid, play vital roles in gastrointestinal physiology and pathology.
- Challenges remain in elucidating the specific functions of individual eicosanoid metabolites.
- Existing knowledge has spurred the development of therapies for NSAID-induced gastroenteropathy and inflammatory bowel disease (IBD).
Purpose of the Study:
- To investigate the roles of cyclooxygenase (COX) isoforms, specifically COX-1 and COX-2, in gastrointestinal function.
- To explore the therapeutic potential of targeted inhibition of eicosanoid-producing enzymes.
- To understand how COX-2 influences intestinal epithelial cell behavior and tumorigenesis.
Main Methods:
- Generation and evaluation of genetically modified mice lacking COX-1 or COX-2 expression.
- Analysis of arachidonic acid metabolism pathways and eicosanoid receptor biology.
- Studies on the effects of COX-2 overexpression in intestinal epithelial cells.
Main Results:
- Progress has been made in understanding arachidonic acid metabolism and eicosanoid receptor interactions.
- The identification of an inducible COX isoform (COX-2) has facilitated research into inflammation, neoplasia, and NSAID-induced gastrointestinal damage.
- COX-2 overexpression in intestinal epithelial cells alters phenotypes, including increased adhesion and reduced apoptosis, suggesting a role in tumorigenesis.
Conclusions:
- Targeted inhibition of COX isoforms holds promise for treating gastrointestinal disorders.
- Further research using COX-deficient mice will enhance understanding of eicosanoid pathways in the gut.
- COX-2 may represent a target for chemopreventive strategies against intestinal cancers.